RAF1 and cancer: Unfortunately, targeting MEK downstream of RAF with drugs such as trametinib17 is ineffective in KRAS-mutant cancers because of feedback mechanisms18 and adverse side-effects,19 and therefore these drugs have been unsuccessful in KRAS-mutant PDAC, CRC and NSCLC.20